LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "keynote 365" as a keyword



Photo from wikipedia

Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.

Sign Up to like & get
recommendations! Published in 2019 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2019.37.15_suppl.5010

Abstract: 5010 Background: Pembro has activity as monotherapy in pts with pretreated advanced mCRPC. A phase 2 study suggested that pembro + enza after progression on enza may have clinical activity. Data from cohort C (pembro… read more here.

Keywords: mcrpc; treatment; study; pembro ... See more keywords

KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—New data after an additional 1 year of follow-up.

Sign Up to like & get
recommendations! Published in 2021 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2021.39.6_suppl.10

Abstract: 10Background: For men with mCRPC, systemic therapies such as docetaxel and cabazitaxel improve survival, but more effective treatments are needed. KEYNOTE-365 (NCT02861573) is a phase 1b/2 study to... read more here.

Keywords: pembrolizumab pembro; 365 cohort; keynote 365; cohort pembrolizumab ... See more keywords
Photo by charlesdeluvio from unsplash

KEYNOTE-365 cohort I: Phase 1b/2 study of pembrolizumab combined with platinum-containing chemotherapy and chemotherapy alone for treatment-emergent neuroendocrine prostate carcinoma (t-NE).

Sign Up to like & get
recommendations! Published in 2022 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2022.40.6_suppl.tps218

Abstract: TPS218 Background: In previously treated adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC), approximately 20% of patients develop t-NE PC, which is aggressive with short overall survival (OS). t-NE PC treatment includes platinum-containing chemotherapy because of t-NE’s… read more here.

Keywords: keynote 365; prostate; pembrolizumab; treatment ... See more keywords